The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population

N V Velde; E Q Wu; A Guo; M Lu; A P Yu; H Sharma; J Liu; C P S Fan; L Shi

doi:10.1038/pcan.2010.49

Back

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population

Journal article

Open access

Peer reviewed

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population

N V Velde, E Q Wu, A Guo, M Lu, A P Yu, H Sharma, J Liu, C P S Fan and L Shi

Prostate cancer and prostatic diseases, Vol.14(1), pp.79-84

03/2011

DOI: 10.1038/pcan.2010.49

PMID: 21173792

Files and links (1)

url

https://doi.org/10.1038/pcan.2010.49View

Published (Version of record) Open Access

Abstract

To examine the effect of timely zoledronic acid (ZA) treatment on clinical outcomes and health care utilization in patients with bone-metastatic prostate cancer. Patients with prostate cancer and bone metastasis were identified in a Veterans Affairs database (01/2002-09/2009). Eligible patients had no documented skeletal-related events (SREs) before the index date (that is, the first bone metastasis diagnosis date). Patients who received early ZA treatment, defined as having a ZA infusion after the index date and before any recorded SREs, were matched 1:1 on propensity score to patients not treated with bisphosphonates (BPs). Risks of SREs, hospitalization and death during the 6-month post-index period were compared between matched cohorts using Kaplan-Meier analyses. Baseline characteristics were well balanced between the matched cohorts (n = 73 per group). 6-month SRE-free survival and hospitalization-free survival were higher in patients receiving timely ZA than patients without BP treatment (91.7 versus 71.5%, P < 0.01; 80.5 versus 66.3%, P = 0.05, respectively). 6-month mortality risk was significantly lower in patients treated with ZA versus those without BP treatment (4.3 versus 13.8%, P = 0.04). Timely ZA intervention in bone-metastatic prostate cancer patients was associated with significant reductions in 6-month risks of SREs, hospitalization and mortality, as compared with no BP treatment.

Aged

Antineoplastic Agents - administration & dosage

Bone Neoplasms - drug therapy

Bone Neoplasms - secondary

Diphosphonates - administration & dosage

Hospitalization - statistics & numerical data

Humans

Imidazoles - administration & dosage

Kaplan-Meier Estimate

Male

Middle Aged

Prostatic Neoplasms - drug therapy

Prostatic Neoplasms - pathology

Retrospective Studies

Risk Assessment

Time Factors

Treatment Outcome

United States

United States Department of Veterans Affairs

Details

Title: Subtitle: The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population
Creators: N V Velde - Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA
E Q Wu
A Guo
M Lu
A P Yu
H Sharma
J Liu
C P S Fan
L Shi
Resource Type: Journal article
Publication Details: Prostate cancer and prostatic diseases, Vol.14(1), pp.79-84
DOI: 10.1038/pcan.2010.49
PMID: 21173792
NLM abbreviation: Prostate Cancer Prostatic Dis
ISSN: 1365-7852
eISSN: 1476-5608
Language: English
Date published: 03/2011
Academic Unit: Health Management and Policy
Record Identifier: 9984214705702771

Metrics

18 Record Views

12 Times Cited - Web of Science